Molecular Assemblies
San Diego, United States· Est.
Enzymatic DNA synthesis platform delivering long, pure oligos faster and cheaper than chemical methods.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Enzymatic DNA synthesis platform delivering long, pure oligos faster and cheaper than chemical methods.
OncologyImmunologyInfectious DiseasesAgricultureNanotechnology
Technology Platform
Fully Enzymatic Synthesis (FES™) uses engineered polymerases at up to 70 °C in a neutral pH to produce long, high‑purity DNA oligos with 99.9% step‑wise incorporation efficiency, eliminating post‑synthesis purification.
Opportunities
Growing demand for long, high‑purity DNA in gene‑therapy, synthetic biology, and DNA‑based vaccines creates a large market tailwinds for its enzymatic platform.
Risk Factors
Technical scaling challenges, competition from alternative synthesis technologies, and price pressure from established chemical synthesis vendors.
Competitive Landscape
Competitors such as Twist Bioscience, Integrated DNA Technologies, and GeneArt rely on traditional phosphoramidite chemistry; Molecular Assemblies differentiates through enzymatic, high‑temperature synthesis that yields longer, purer oligos with faster turnaround.